Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32272850,zeta potential,A particle size (196.4 ± 10.05 nm) with smooth and spherical shape alongwith zeta potential (11.8 ± 0.91 mV) and drug-content (44.64 ± 2.91 µg/mg) was observed.,A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272850/),mv,11.8,5102,DB00588,Fluticasone Propionate
,32272850,elution time,"BUD 0.75 min and 431.61/323.16 m/z whereas Fluticasone (IS) 1.16 min and 501.42/313.31 m/z, elution time and transition respectively.",A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272850/),min,1.16,5103,DB00588,Fluticasone Propionate
,32272850,elution time,"BUD 0.75 min and 431.61/323.16 m/z whereas Fluticasone (IS) 1.16 min and 501.42/313.31 m/z, elution time and transition respectively.",A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272850/),[m] / [z],501.42,5104,DB00588,Fluticasone Propionate
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,1.1,5548,DB00588,Fluticasone Propionate
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,4.0,5549,DB00588,Fluticasone Propionate
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,2.6,5550,DB00588,Fluticasone Propionate
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,1.1,5551,DB00588,Fluticasone Propionate
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,4.0,5552,DB00588,Fluticasone Propionate
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,2.6,5553,DB00588,Fluticasone Propionate
,30427594,t½,"On day 1, geometric mean t½ of UMEC and VI was 0.36 and 0.52 hours, respectively; t½ of FF was not representative because of nonquantifiable concentration data.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),h,0.36,6068,DB00588,Fluticasone Propionate
,30427594,t½,"On day 1, geometric mean t½ of UMEC and VI was 0.36 and 0.52 hours, respectively; t½ of FF was not representative because of nonquantifiable concentration data.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),h,0.52,6069,DB00588,Fluticasone Propionate
,30427594,Cmax,"On days 1 and 7, geometric mean Cmax of FF was 10.46 and 27.32 pg/mL, respectively; Cmax of UMEC was 144.14 and 241.35 pg/mL, respectively; and Cmax of VI was 120.42 and 196.78 pg/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[pg] / [ml],10.46,6070,DB00588,Fluticasone Propionate
,30427594,Cmax,"On days 1 and 7, geometric mean Cmax of FF was 10.46 and 27.32 pg/mL, respectively; Cmax of UMEC was 144.14 and 241.35 pg/mL, respectively; and Cmax of VI was 120.42 and 196.78 pg/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[pg] / [ml],27.32,6071,DB00588,Fluticasone Propionate
,30427594,Cmax,"On days 1 and 7, geometric mean Cmax of FF was 10.46 and 27.32 pg/mL, respectively; Cmax of UMEC was 144.14 and 241.35 pg/mL, respectively; and Cmax of VI was 120.42 and 196.78 pg/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[pg] / [ml],144.14,6072,DB00588,Fluticasone Propionate
,30427594,Cmax,"On days 1 and 7, geometric mean Cmax of FF was 10.46 and 27.32 pg/mL, respectively; Cmax of UMEC was 144.14 and 241.35 pg/mL, respectively; and Cmax of VI was 120.42 and 196.78 pg/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[pg] / [ml],241.35,6073,DB00588,Fluticasone Propionate
,30427594,Cmax,"On days 1 and 7, geometric mean Cmax of FF was 10.46 and 27.32 pg/mL, respectively; Cmax of UMEC was 144.14 and 241.35 pg/mL, respectively; and Cmax of VI was 120.42 and 196.78 pg/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[pg] / [ml],120.42,6074,DB00588,Fluticasone Propionate
,30427594,Cmax,"On days 1 and 7, geometric mean Cmax of FF was 10.46 and 27.32 pg/mL, respectively; Cmax of UMEC was 144.14 and 241.35 pg/mL, respectively; and Cmax of VI was 120.42 and 196.78 pg/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[pg] / [ml],196.78,6075,DB00588,Fluticasone Propionate
,30427594,AUC0-t,"AUC0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC0-t of VI, 42.46 and 101.12 pg·h/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[h·pg] / [ml],1.77,6076,DB00588,Fluticasone Propionate
,30427594,AUC0-t,"AUC0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC0-t of VI, 42.46 and 101.12 pg·h/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[h·pg] / [ml],276.96,6077,DB00588,Fluticasone Propionate
,30427594,AUC0-t,"AUC0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC0-t of VI, 42.46 and 101.12 pg·h/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[h·pg] / [ml],28.44,6078,DB00588,Fluticasone Propionate
,30427594,AUC0-t,"AUC0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC0-t of VI, 42.46 and 101.12 pg·h/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[h·pg] / [ml],117.19,6079,DB00588,Fluticasone Propionate
,30427594,AUC0-t,"AUC0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC0-t of VI, 42.46 and 101.12 pg·h/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[h·pg] / [ml],42.46,6080,DB00588,Fluticasone Propionate
,30427594,AUC0-t,"AUC0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC0-t of VI, 42.46 and 101.12 pg·h/mL, respectively.",Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427594/),[h·pg] / [ml],101.12,6081,DB00588,Fluticasone Propionate
,26314817,tmax,Median tmax (60.0-60.6 minutes) and median t1/2 (9.1-9.8 hours) were comparable across the three treatments.,"Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26314817/),min,60.0-60.6,10407,DB00588,Fluticasone Propionate
,26314817,t1/2,Median tmax (60.0-60.6 minutes) and median t1/2 (9.1-9.8 hours) were comparable across the three treatments.,"Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26314817/),h,9.1-9.8,10408,DB00588,Fluticasone Propionate
,34089712,MIC,"Stochastic simulations to establish initial dosing regimens to maximize the time above the MIC showed that the mean probabilities to achieve the PK/PD target (PTA) for microorganisms with a MIC of 2 and 8 µg/mL were 0.8 and 0.7 following i.v. bolus of 250 and 500 mg/m2/dose q8h, respectively.",Optimizing Meropenem Therapy for Severe Nosocomial Infections in Neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089712/),[μg] / [ml],2,15598,DB00588,Fluticasone Propionate
,34089712,MIC,"Stochastic simulations to establish initial dosing regimens to maximize the time above the MIC showed that the mean probabilities to achieve the PK/PD target (PTA) for microorganisms with a MIC of 2 and 8 µg/mL were 0.8 and 0.7 following i.v. bolus of 250 and 500 mg/m2/dose q8h, respectively.",Optimizing Meropenem Therapy for Severe Nosocomial Infections in Neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089712/),[μg] / [ml],8,15599,DB00588,Fluticasone Propionate
,27128459,Cmax,"Following repeat dosing, the arithmetic mean (SD) FF Cmax was 26.71 pg/mL (9.16) at 31 minutes post-dose.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate, a novel inhaled corticosteroid, in children aged 5-11 years with persistent asthma: A randomized trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128459/),[pg] / [ml],26.71,17863,DB00588,Fluticasone Propionate
,27128459,AUC(0-t),Arithmetic mean (SD) FF AUC(0-t) was 121.44 pg h/mL (83.04).,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate, a novel inhaled corticosteroid, in children aged 5-11 years with persistent asthma: A randomized trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128459/),[h·pg] / [ml],121.44,17864,DB00588,Fluticasone Propionate
,11140431,maximum plasma FP concentration (Cmax),"After 4 weeks, the maximum plasma FP concentration (Cmax) in this subgroup was 0.096 microg/L [95% confidence interval (CI) 0.066-0.141] and the area under the plasma FP concentration-time curve up to the last quantifiable concentration (AUClast) was 0.491 microg/L x h (95% CI: 0.256-0.940).",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140431/),[μg] / [l],0.096,20999,DB00588,Fluticasone Propionate
,11140431,area under the plasma FP concentration-time curve up to the last quantifiable concentration (AUClast),"After 4 weeks, the maximum plasma FP concentration (Cmax) in this subgroup was 0.096 microg/L [95% confidence interval (CI) 0.066-0.141] and the area under the plasma FP concentration-time curve up to the last quantifiable concentration (AUClast) was 0.491 microg/L x h (95% CI: 0.256-0.940).",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140431/),[μg] / [h·l],0.491,21000,DB00588,Fluticasone Propionate
,11140433,AUC50),"The systemic exposure to FP that resulted in half the maximum possible reduction in plasma cortisol levels (AUC50) was 3.2 microg/L x h (95% CI: 2.8, 3.7 microg/L x h); this equates approximately to the plasma FP concentration obtained after administration of a 1000 microg inhaled dose.",The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140433/),[μg] / [h·l],3.2,31633,DB00588,Fluticasone Propionate
,23735179,maximum heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,66,38793,DB00588,Fluticasone Propionate
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,70,38794,DB00588,Fluticasone Propionate
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,73,38795,DB00588,Fluticasone Propionate
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,66,38796,DB00588,Fluticasone Propionate
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,64,38797,DB00588,Fluticasone Propionate
,10930963,absorption half-life,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),min,10,41262,DB00588,Fluticasone Propionate
,10930963,absorption half-life,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),min,11.3,41263,DB00588,Fluticasone Propionate
,10930963,elimination half-lives,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),h,2.4,41264,DB00588,Fluticasone Propionate
,10930963,elimination half-lives,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),h,7.8,41265,DB00588,Fluticasone Propionate
,10930963,V/F ratio,"Consistent with previous reports of FP's higher volume of distribution (V) and lower systemic bioavailability (F), the V/F ratio was lower for BUD than FP (498 l vs 8100 l).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),l,498,41266,DB00588,Fluticasone Propionate
,10930963,V/F ratio,"Consistent with previous reports of FP's higher volume of distribution (V) and lower systemic bioavailability (F), the V/F ratio was lower for BUD than FP (498 l vs 8100 l).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),l,8100,41267,DB00588,Fluticasone Propionate
,31732149,C,"With Xhance® 186 μg, the geometric least squares mean (LSM) Cmax was higher than with Flonase® 400 μg (16.02 vs 11.66 pg/mL, respectively; geometric mean ratio [GMR], 137.42%) and the geometric LSM AUC0-∞ values were similar (97.30 vs 99.61 pg · h/mL; GMR, 97.78%).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[pg] / [ml],16.02,42872,DB00588,Fluticasone Propionate
,31732149,C,"With Xhance® 186 μg, the geometric least squares mean (LSM) Cmax was higher than with Flonase® 400 μg (16.02 vs 11.66 pg/mL, respectively; geometric mean ratio [GMR], 137.42%) and the geometric LSM AUC0-∞ values were similar (97.30 vs 99.61 pg · h/mL; GMR, 97.78%).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[pg] / [ml],11.66,42873,DB00588,Fluticasone Propionate
,31732149,Cmax,"With Xhance® 372 μg, the geometric LSM Cmax and AUC0-∞ were higher than with Flonase® 400 μg (Cmax, 23.50 vs 11.66 pg/mL [GMR, 201.53%]; AUC0-∞, 146.61 vs 99.61 pg · h/mL [GMR, 147.19%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[pg] / [ml],23.50,42874,DB00588,Fluticasone Propionate
,31732149,Cmax,"With Xhance® 372 μg, the geometric LSM Cmax and AUC0-∞ were higher than with Flonase® 400 μg (Cmax, 23.50 vs 11.66 pg/mL [GMR, 201.53%]; AUC0-∞, 146.61 vs 99.61 pg · h/mL [GMR, 147.19%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[pg] / [ml],11.66,42875,DB00588,Fluticasone Propionate
,31732149,AUC0-∞,"With Xhance® 372 μg, the geometric LSM Cmax and AUC0-∞ were higher than with Flonase® 400 μg (Cmax, 23.50 vs 11.66 pg/mL [GMR, 201.53%]; AUC0-∞, 146.61 vs 99.61 pg · h/mL [GMR, 147.19%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[h·pg] / [ml],146.61,42876,DB00588,Fluticasone Propionate
,31732149,AUC0-∞,"With Xhance® 372 μg, the geometric LSM Cmax and AUC0-∞ were higher than with Flonase® 400 μg (Cmax, 23.50 vs 11.66 pg/mL [GMR, 201.53%]; AUC0-∞, 146.61 vs 99.61 pg · h/mL [GMR, 147.19%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[h·pg] / [ml],99.61,42877,DB00588,Fluticasone Propionate
,31732149,Cmax,"In part 2, the geometric LSM Cmax and AUC0-∞ values were lower with Xhance® 372 μg than with Flovent® HFA 440 μg (Cmax, 25.28 vs 40.02 pg/mL [GMR, 63.18%]; AUC0-∞, 205.78 vs 415.16 pg · h/mL [GMR, 49.57%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[pg] / [ml],25.28,42878,DB00588,Fluticasone Propionate
,31732149,Cmax,"In part 2, the geometric LSM Cmax and AUC0-∞ values were lower with Xhance® 372 μg than with Flovent® HFA 440 μg (Cmax, 25.28 vs 40.02 pg/mL [GMR, 63.18%]; AUC0-∞, 205.78 vs 415.16 pg · h/mL [GMR, 49.57%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[pg] / [ml],40.02,42879,DB00588,Fluticasone Propionate
,31732149,AUC0-∞,"In part 2, the geometric LSM Cmax and AUC0-∞ values were lower with Xhance® 372 μg than with Flovent® HFA 440 μg (Cmax, 25.28 vs 40.02 pg/mL [GMR, 63.18%]; AUC0-∞, 205.78 vs 415.16 pg · h/mL [GMR, 49.57%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[h·pg] / [ml],205.78,42880,DB00588,Fluticasone Propionate
,31732149,AUC0-∞,"In part 2, the geometric LSM Cmax and AUC0-∞ values were lower with Xhance® 372 μg than with Flovent® HFA 440 μg (Cmax, 25.28 vs 40.02 pg/mL [GMR, 63.18%]; AUC0-∞, 205.78 vs 415.16 pg · h/mL [GMR, 49.57%]).",A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732149/),[h·pg] / [ml],415.16,42881,DB00588,Fluticasone Propionate
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,30.8,49510,DB00588,Fluticasone Propionate
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,8.0,49511,DB00588,Fluticasone Propionate
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,29.5,49512,DB00588,Fluticasone Propionate
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,7.6,49513,DB00588,Fluticasone Propionate
less,15102872,t(max),All formulations were rapidly absorbed (t(max) less than 1 h).,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,1,50060,DB00588,Fluticasone Propionate
,15102872,terminal half-lives,"The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,2.2,50061,DB00588,Fluticasone Propionate
,15102872,terminal half-lives,"The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,1.8,50062,DB00588,Fluticasone Propionate
,15102872,terminal half-lives,"The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,4.2,50063,DB00588,Fluticasone Propionate
,15102872,peak concentrations (C(max)),Mean peak concentrations (C(max)) were 139 +/- 57 pg/mL with LE 400 microg and 164 +/- 54 pg/mL with LE 800 microg and thus fairly independent from dose.,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[pg] / [ml],139,50064,DB00588,Fluticasone Propionate
,15102872,peak concentrations (C(max)),Mean peak concentrations (C(max)) were 139 +/- 57 pg/mL with LE 400 microg and 164 +/- 54 pg/mL with LE 800 microg and thus fairly independent from dose.,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[pg] / [ml],164,50065,DB00588,Fluticasone Propionate
,15102872,C(max),The 200-microg FP treatment resulted in a C(max) of only 15.5 +/- 5.9 pg/mL.,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[pg] / [ml],15.5,50066,DB00588,Fluticasone Propionate
,15102872,AUC(0-t),"Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[h·pg] / [ml],193,50067,DB00588,Fluticasone Propionate
,15102872,AUC(0-t),"Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[h·pg] / [ml],300,50068,DB00588,Fluticasone Propionate
,15102872,AUC(0-t),"Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[h·pg] / [ml],40,50069,DB00588,Fluticasone Propionate
,11140430,area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity),Systemic exposure to FP after administration of a single 1000 microg inhaled dose of FP via the 2 powder devices was similar; the area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity) was 2.08 microg/L x h [95% confidence intervals (CI): 1.63-2.64] for Diskhaler and 2.49 microg/L x h (95% CI: 2.09-2.96) for Diskus.,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [h·l],2.08,52896,DB00588,Fluticasone Propionate
,11140430,area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity),Systemic exposure to FP after administration of a single 1000 microg inhaled dose of FP via the 2 powder devices was similar; the area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity) was 2.08 microg/L x h [95% confidence intervals (CI): 1.63-2.64] for Diskhaler and 2.49 microg/L x h (95% CI: 2.09-2.96) for Diskus.,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [h·l],2.49,52897,DB00588,Fluticasone Propionate
,11140430,Maximum plasma FP concentration (Cmax),Maximum plasma FP concentration (Cmax) was 0.34 microg/L for both devices.,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [l],0.34,52898,DB00588,Fluticasone Propionate
,11140430,bioavailability,"Mean bioavailability values via the Diskhaler and Diskus were 11.9% (95% CI: 9.0-15.7%) and 16.6% (95% CI: 13.6-20.3%), respectively.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),%,11.9,52899,DB00588,Fluticasone Propionate
,11140430,bioavailability,"Mean bioavailability values via the Diskhaler and Diskus were 11.9% (95% CI: 9.0-15.7%) and 16.6% (95% CI: 13.6-20.3%), respectively.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),%,16.6,52900,DB00588,Fluticasone Propionate
,11140430,AUC up to 12 hours (AUC12h),"After dose 15, the AUC up to 12 hours (AUC12h) was 2.25 microg/L x h and Cmax was 0.38 microg/L.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [h·l],2.25,52901,DB00588,Fluticasone Propionate
,11140430,Cmax,"After dose 15, the AUC up to 12 hours (AUC12h) was 2.25 microg/L x h and Cmax was 0.38 microg/L.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [l],0.38,52902,DB00588,Fluticasone Propionate
,11140430,steady-state to single dose accumulation ratio,The mean steady-state to single dose accumulation ratio after twice-daily administration was 1.49 (95% CI: 1.36-1.62).,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),,1.49,52903,DB00588,Fluticasone Propionate
,10856145,peak expiratory flow,"Treatment with FP was more effective than treatment with zafirlukast in increasing morning FEV(1) (by 0.42 L vs 0.20 L over baseline, P <.001), morning peak expiratory flow (by 49.94 L/min vs 11.68 L/min over baseline, P <. 001), and evening PEF (by 38.91 L/min vs 10.50 L/min over baseline, P <.001).",Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856145/),[l] / [min],49.94,52904,DB00588,Fluticasone Propionate
,10856145,peak expiratory flow,"Treatment with FP was more effective than treatment with zafirlukast in increasing morning FEV(1) (by 0.42 L vs 0.20 L over baseline, P <.001), morning peak expiratory flow (by 49.94 L/min vs 11.68 L/min over baseline, P <. 001), and evening PEF (by 38.91 L/min vs 10.50 L/min over baseline, P <.001).",Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856145/),[l] / [min],11.68,52905,DB00588,Fluticasone Propionate
,15114430,plasma AUC,MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h).,Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114430/),[pM] / [h·l],123,57921,DB00588,Fluticasone Propionate
,15114430,plasma AUC,MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h).,Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114430/),[pM] / [h·l],112,57922,DB00588,Fluticasone Propionate
,29493402,time to maximum concentration (tmax),Median salmeterol time to maximum concentration (tmax) was 4.0 minutes.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),min,4.0,60836,DB00588,Fluticasone Propionate
,29493402,tmax,Median fluticasone propionate tmax was from 1.5 to 2.0 hours.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,1.5 to 2.0,60837,DB00588,Fluticasone Propionate
,29493402,Terminal elimination half-life,Terminal elimination half-life was 11 hours for salmeterol and 9-10 hours for fluticasone propionate.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,11,60838,DB00588,Fluticasone Propionate
,29493402,Terminal elimination half-life,Terminal elimination half-life was 11 hours for salmeterol and 9-10 hours for fluticasone propionate.,Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493402/),h,9-10,60839,DB00588,Fluticasone Propionate
<,16120068,trough concentrations,ATV trough concentrations exhibited substantial intersubject variability (<25-2108 microg l(-1)).,Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120068/),[μg] / [l],25-2108,64079,DB00588,Fluticasone Propionate
,17137894,FPC,The mean +/- SD FPC was 107 +/- 30 pg/mL after conventional VHC and 186 +/- 134 pg/mL after the antistatic VHC (P = .03).,Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17137894/),[pg] / [ml],107,68593,DB00588,Fluticasone Propionate
,17137894,FPC,The mean +/- SD FPC was 107 +/- 30 pg/mL after conventional VHC and 186 +/- 134 pg/mL after the antistatic VHC (P = .03).,Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17137894/),[pg] / [ml],186,68594,DB00588,Fluticasone Propionate
,9551705,terminal half-life,FP showed a dose-independent terminal half-life with a mean (SD) of 6.0 (0.7) h.,Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),h,6.0,69896,DB00588,Fluticasone Propionate
,9551705,Maximum serum concentrations,"Maximum serum concentrations occurred 1.0 (0.5) h after administration, ranging from 90 pg.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),pg,90,69897,DB00588,Fluticasone Propionate
,9551705,mean absorption time,"This, together with an estimated mean absorption time of nearly 5 h and a known oral bioavailability of less than 1%, indicates prolonged residence at and slow absorption from the lungs.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),h,5,69898,DB00588,Fluticasone Propionate
less,9551705,oral bioavailability,"This, together with an estimated mean absorption time of nearly 5 h and a known oral bioavailability of less than 1%, indicates prolonged residence at and slow absorption from the lungs.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%,1,69899,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,159,69900,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,186,69901,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,257,69902,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,372,69903,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,107,69904,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,202,69905,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%·h,348,69906,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%,23.6,69907,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%,33.8,69908,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%,51.0,69909,DB00588,Fluticasone Propionate
,9551705,cumulative systemic-effect parameters,"For doses of 0.25, 0.50, 1.0 and 3.0 mg FP, the PK/PD-based cumulative systemic-effect parameters were 159, 186, 257 and 372% .h for lymphocyte suppression, 107, 186, 202 and 348% .h for granulocyte induction and 23.6%, 33.8%, 51.0% and 73.6% for cortisol reduction, respectively.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),%,73.6,69910,DB00588,Fluticasone Propionate
,9551705,EC50,"The measured in vivo EC50 values, 30 pg.",Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551705/),pg,30,69911,DB00588,Fluticasone Propionate
,10919683,peak expiratory flow (PEF),"The improvement in mean morning peak expiratory flow (PEF) after 7 days of treatment was approximately 12 l min(-1) in both groups, rising to approximately 22 l min(-1) at the end of the 4-week treatment period.",Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919683/),[l] / [min],12,75309,DB00588,Fluticasone Propionate
,10919683,peak expiratory flow (PEF),"The improvement in mean morning peak expiratory flow (PEF) after 7 days of treatment was approximately 12 l min(-1) in both groups, rising to approximately 22 l min(-1) at the end of the 4-week treatment period.",Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919683/),[l] / [min],22,75310,DB00588,Fluticasone Propionate
,21933835,AUC,The population mean AUC following FP with AeroChamber Plus with Facemask was 97.45 pg·h·mL(-1) (95% CI 85.49-113.32 pg·h·mL(-1)) and with Babyhaler was 51.55 pg·h·mL(-1) (95% CI 34.45-64.46 pg·h·mL(-1)).,Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21933835/),[h·pg] / [ml],97.45,75797,DB00588,Fluticasone Propionate
,21933835,AUC,The population mean AUC following FP with AeroChamber Plus with Facemask was 97.45 pg·h·mL(-1) (95% CI 85.49-113.32 pg·h·mL(-1)) and with Babyhaler was 51.55 pg·h·mL(-1) (95% CI 34.45-64.46 pg·h·mL(-1)).,Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21933835/),[h·pg] / [ml],51.55,75798,DB00588,Fluticasone Propionate
,21933835,relative bioavailability,The relative bioavailability (Babyhaler/AeroChamber Plus) was 0.53 (95% CI 0.30-0.75).,Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21933835/),,0.53,75799,DB00588,Fluticasone Propionate
<,23184737,oral bioavailability,The bioavailability of both inhaled FF and FP represents absorption from the lung as the oral bioavailability from the swallowed portion of the inhaled dose is negligible (<1.5 %).,"Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),%,1.5,75878,DB00588,Fluticasone Propionate
,23184737,terminal elimination half-life (t(½β)),"The terminal elimination half-life (t(½β)) for inhaled FF was considerably longer (range 17-24 h) than the t(½β) estimated for intravenous FF (14 h), whereas t(½β) for FP was similar whether inhaled or given intravenously (11 and 14 h, respectively).","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,17-24,75879,DB00588,Fluticasone Propionate
,23184737,t(½β),"The terminal elimination half-life (t(½β)) for inhaled FF was considerably longer (range 17-24 h) than the t(½β) estimated for intravenous FF (14 h), whereas t(½β) for FP was similar whether inhaled or given intravenously (11 and 14 h, respectively).","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,14,75880,DB00588,Fluticasone Propionate
,23184737,t(½β),"The terminal elimination half-life (t(½β)) for inhaled FF was considerably longer (range 17-24 h) than the t(½β) estimated for intravenous FF (14 h), whereas t(½β) for FP was similar whether inhaled or given intravenously (11 and 14 h, respectively).","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,11,75881,DB00588,Fluticasone Propionate
,23184737,lung mean absorption time,"The lung mean absorption time for FF was approximately 7 h irrespective of formulation, which was considerably longer than FP (2.1 h).","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,7,75882,DB00588,Fluticasone Propionate
,23184737,lung mean absorption time,"The lung mean absorption time for FF was approximately 7 h irrespective of formulation, which was considerably longer than FP (2.1 h).","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,2.1,75883,DB00588,Fluticasone Propionate
,23184737,time for 90 % absorption,"The time for 90 % absorption from the lung was significantly longer for FF (20-30 h) than for FP (8 h), indicating a significantly longer lung retention time for FF.","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,20-30,75884,DB00588,Fluticasone Propionate
,23184737,time for 90 % absorption,"The time for 90 % absorption from the lung was significantly longer for FF (20-30 h) than for FP (8 h), indicating a significantly longer lung retention time for FF.","Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184737/),h,8,75885,DB00588,Fluticasone Propionate
,8930781,E50,The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations; these results were not dose dependent.,Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930781/),[ng] / [ml],0.134,78139,DB00588,Fluticasone Propionate
,8930781,E50,The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations; these results were not dose dependent.,Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930781/),[ng] / [ml],0.013,78140,DB00588,Fluticasone Propionate
,8799519,Vss,"FP was extensively distributed within the body (Vss 3181), rapidly cleared (CL 1.1 l min-1) with a terminal elimination half-life of 7.8 h and a mean residence time of 4.9 h.",Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799519/),,3181,83602,DB00588,Fluticasone Propionate
,8799519,CL,"FP was extensively distributed within the body (Vss 3181), rapidly cleared (CL 1.1 l min-1) with a terminal elimination half-life of 7.8 h and a mean residence time of 4.9 h.",Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799519/),[l] / [min],1.1,83603,DB00588,Fluticasone Propionate
,8799519,terminal elimination half-life,"FP was extensively distributed within the body (Vss 3181), rapidly cleared (CL 1.1 l min-1) with a terminal elimination half-life of 7.8 h and a mean residence time of 4.9 h.",Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799519/),h,7.8,83604,DB00588,Fluticasone Propionate
,8799519,mean residence time,"FP was extensively distributed within the body (Vss 3181), rapidly cleared (CL 1.1 l min-1) with a terminal elimination half-life of 7.8 h and a mean residence time of 4.9 h.",Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799519/),h,4.9,83605,DB00588,Fluticasone Propionate
,18694910,oral bioavailability,"Oral absorption was rapid and estimated at approximately 30%, although the oral bioavailability was markedly lower at 1.6%, limited by extensive first-pass metabolism.","Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694910/),%,1.6,87437,DB00588,Fluticasone Propionate
,18694910,Plasma clearance,"Plasma clearance was 58.3 l/h, with a volume of distribution of 642 liters and a terminal elimination half-life of 15.3 h.","Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694910/),[l] / [h],58.3,87438,DB00588,Fluticasone Propionate
,18694910,volume of distribution,"Plasma clearance was 58.3 l/h, with a volume of distribution of 642 liters and a terminal elimination half-life of 15.3 h.","Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694910/),l,642,87439,DB00588,Fluticasone Propionate
,18694910,terminal elimination half-life,"Plasma clearance was 58.3 l/h, with a volume of distribution of 642 liters and a terminal elimination half-life of 15.3 h.","Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694910/),h,15.3,87440,DB00588,Fluticasone Propionate
,18694910,recovery of radioactivity,"Mean recovery of radioactivity was approximately 92 and 102% at 216 and 168 h after i.v. and p.o. administration, respectively, with most (at least 90%) recovered in the feces.","Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694910/),%,92,87441,DB00588,Fluticasone Propionate
,18694910,recovery of radioactivity,"Mean recovery of radioactivity was approximately 92 and 102% at 216 and 168 h after i.v. and p.o. administration, respectively, with most (at least 90%) recovered in the feces.","Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694910/),%,102,87442,DB00588,Fluticasone Propionate
,26219638,tmax,Median tmax (60.0-60.6 minutes) and median t1/2 (9.1-9.8 hours) were comparable across the three treatments.,"Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus Diskus and metered-dose inhalers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26219638/),min,60.0-60.6,87874,DB00588,Fluticasone Propionate
,26219638,t1/2,Median tmax (60.0-60.6 minutes) and median t1/2 (9.1-9.8 hours) were comparable across the three treatments.,"Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus Diskus and metered-dose inhalers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26219638/),h,9.1-9.8,87875,DB00588,Fluticasone Propionate
,23232038,Tmax,In all subjects VI was rapidly absorbed (healthy subjects median Tmax at 5 min; asthma and COPD subjects median Tmax at 10 min) with systemic exposure increasing in an approximately dose proportional manner across the VI dose range.,"Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23232038/),min,5,88766,DB00588,Fluticasone Propionate
,23232038,Tmax,In all subjects VI was rapidly absorbed (healthy subjects median Tmax at 5 min; asthma and COPD subjects median Tmax at 10 min) with systemic exposure increasing in an approximately dose proportional manner across the VI dose range.,"Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23232038/),min,10,88767,DB00588,Fluticasone Propionate
,33768368,mass aerodynamic diameter,"Three fluticasone propionate (FP) dry powder inhaler (DPI) formulations (A-4.5, B-3.8, and C-3.7), differing only in type and composition of lactose fines, exhibited median mass aerodynamic diameter (MMAD) of 4.5 μm (A-4.5), 3.8 μm (B-3.8), and 3.7 μm (C-3.7) and varied in dissolution rates (A-4.5 slower than B-3.8 and C-3.7).",Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768368/),μm,4.5,91849,DB00588,Fluticasone Propionate
,33768368,mass aerodynamic diameter,"Three fluticasone propionate (FP) dry powder inhaler (DPI) formulations (A-4.5, B-3.8, and C-3.7), differing only in type and composition of lactose fines, exhibited median mass aerodynamic diameter (MMAD) of 4.5 μm (A-4.5), 3.8 μm (B-3.8), and 3.7 μm (C-3.7) and varied in dissolution rates (A-4.5 slower than B-3.8 and C-3.7).",Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768368/),μm,3.8,91850,DB00588,Fluticasone Propionate
,33768368,mass aerodynamic diameter,"Three fluticasone propionate (FP) dry powder inhaler (DPI) formulations (A-4.5, B-3.8, and C-3.7), differing only in type and composition of lactose fines, exhibited median mass aerodynamic diameter (MMAD) of 4.5 μm (A-4.5), 3.8 μm (B-3.8), and 3.7 μm (C-3.7) and varied in dissolution rates (A-4.5 slower than B-3.8 and C-3.7).",Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768368/),μm,3.7,91851,DB00588,Fluticasone Propionate
,33768368,DNF,"The DNF was 1.00 for A-4.5, 1.32 for B-3.8, and 1.21 for C-3.7.",Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768368/),,1.00,91852,DB00588,Fluticasone Propionate
,33768368,DNF,"The DNF was 1.00 for A-4.5, 1.32 for B-3.8, and 1.21 for C-3.7.",Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768368/),,1.32,91853,DB00588,Fluticasone Propionate
,33768368,DNF,"The DNF was 1.00 for A-4.5, 1.32 for B-3.8, and 1.21 for C-3.7.",Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768368/),,1.21,91854,DB00588,Fluticasone Propionate
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],100.3,95830,DB00588,Fluticasone Propionate
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],181.0,95831,DB00588,Fluticasone Propionate
,11140429,maximum plasma FP concentrations,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),[μg] / [l],0.56,98123,DB00588,Fluticasone Propionate
,11140429,maximum plasma FP concentrations,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),[μg] / [l],0.54,98124,DB00588,Fluticasone Propionate
,11140429,bioavailability,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),%,26.4,98125,DB00588,Fluticasone Propionate
,11140429,bioavailability,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),%,28.6,98126,DB00588,Fluticasone Propionate
,32485781,Tmax,"Median Tmax was 1.33 h (range=0.75-6.00), mean Cmax was 13.05±7.59 pg/mL, mean AUCt was 148.48±77.76 pg/mL*h, mean AUCinf was 279.07±187.81 pg/mL*h, and mean t1/2 was 31.67±29.23 h.",The Pharmacokinetics of Fluticasone Furoate Given Intranasally in Healthy Subjects Using an Ultra-Sensitive Analytical Assay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32485781/),h,1.33,98420,DB00588,Fluticasone Propionate
,32485781,Cmax,"Median Tmax was 1.33 h (range=0.75-6.00), mean Cmax was 13.05±7.59 pg/mL, mean AUCt was 148.48±77.76 pg/mL*h, mean AUCinf was 279.07±187.81 pg/mL*h, and mean t1/2 was 31.67±29.23 h.",The Pharmacokinetics of Fluticasone Furoate Given Intranasally in Healthy Subjects Using an Ultra-Sensitive Analytical Assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32485781/),[pg] / [ml],13.05,98421,DB00588,Fluticasone Propionate
,32485781,AUCt,"Median Tmax was 1.33 h (range=0.75-6.00), mean Cmax was 13.05±7.59 pg/mL, mean AUCt was 148.48±77.76 pg/mL*h, mean AUCinf was 279.07±187.81 pg/mL*h, and mean t1/2 was 31.67±29.23 h.",The Pharmacokinetics of Fluticasone Furoate Given Intranasally in Healthy Subjects Using an Ultra-Sensitive Analytical Assay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32485781/),[pg] / [h·ml],148.48,98422,DB00588,Fluticasone Propionate
,32485781,AUCinf,"Median Tmax was 1.33 h (range=0.75-6.00), mean Cmax was 13.05±7.59 pg/mL, mean AUCt was 148.48±77.76 pg/mL*h, mean AUCinf was 279.07±187.81 pg/mL*h, and mean t1/2 was 31.67±29.23 h.",The Pharmacokinetics of Fluticasone Furoate Given Intranasally in Healthy Subjects Using an Ultra-Sensitive Analytical Assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32485781/),[pg] / [h·ml],279.07,98423,DB00588,Fluticasone Propionate
,32485781,t1/2,"Median Tmax was 1.33 h (range=0.75-6.00), mean Cmax was 13.05±7.59 pg/mL, mean AUCt was 148.48±77.76 pg/mL*h, mean AUCinf was 279.07±187.81 pg/mL*h, and mean t1/2 was 31.67±29.23 h.",The Pharmacokinetics of Fluticasone Furoate Given Intranasally in Healthy Subjects Using an Ultra-Sensitive Analytical Assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32485781/),h,31.67,98424,DB00588,Fluticasone Propionate
,33668571,target release,In vitro drug release studies showed a target release of 1 mg/day of fluticasone.,Steroid Eluting Esophageal-Targeted Drug Delivery Devices for Treatment of Eosinophilic Esophagitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33668571/),[mg] / [d],1,98456,DB00588,Fluticasone Propionate
,30431426,AUC0-t,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],"1,622.64",98462,DB00588,Fluticasone Propionate
,30431426,AUC0-t,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],"1,487.52",98463,DB00588,Fluticasone Propionate
,30431426,Cmax,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],151.36,98464,DB00588,Fluticasone Propionate
,30431426,Cmax,"In study 1, in subjects administered FS Spiromax, the mean (standard deviation (SD)) FP AUC0-t and Cmax were 1,622.64 (419.44) pg×h/mL and 151.36 (40.37) pg/mL, respectively, vs. 1,487.52 (341.25) pg×h/mL and 137.57 (33.64) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],137.57,98465,DB00588,Fluticasone Propionate
,30431426,AUC0-t,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],408.42,98466,DB00588,Fluticasone Propionate
,30431426,AUC0-t,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[h·pg] / [ml],401.79,98467,DB00588,Fluticasone Propionate
,30431426,Cmax,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],269.48,98468,DB00588,Fluticasone Propionate
,30431426,Cmax,"Mean (SD) SAL AUC0-t and Cmax with FS Spiromax were 408.42 (155.40) pg×h/mL and 269.48 (105.74) pg/mL, respectively, vs. 401.79 (125.32) pg×h/mL and 265.66 (87.28) pg/mL with Seretide Accuhaler.",Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30431426/),[pg] / [ml],265.66,98469,DB00588,Fluticasone Propionate
,27216137,AUC0-12,"FEV1 AUC0-12 was significantly higher with all FS MDPI doses and FS DPI versus Fp MDPI (p < 0.0001), and with FS MDPI 100/50 μg versus FS DPI (least squares [LS] mean, 57.88 mL; p = 0.0017).",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,57.88,104453,DB00588,Fluticasone Propionate
,27216137,AUC0-12,"FEV1 AUC0-12 trended toward higher efficacy with FS MDPI 100/25 μg (LS mean, 34.14 mL; p = 0.0624) and was comparable with FS MDPI 100/12.5 μg (LS mean, 3.42 mL; p = 0.8503) versus FS DPI.",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,34.14,104454,DB00588,Fluticasone Propionate
,27216137,AUC0-12,"FEV1 AUC0-12 trended toward higher efficacy with FS MDPI 100/25 μg (LS mean, 34.14 mL; p = 0.0624) and was comparable with FS MDPI 100/12.5 μg (LS mean, 3.42 mL; p = 0.8503) versus FS DPI.",Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27216137/),ml,3.42,104455,DB00588,Fluticasone Propionate
,22796247,morning,"However, morning trough values might have been affected by higher placebo response after morning dosing (18.8 vs 8.8 L/min).","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],18.8,105321,DB00588,Fluticasone Propionate
,22796247,trough,"However, morning trough values might have been affected by higher placebo response after morning dosing (18.8 vs 8.8 L/min).","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],18.8,105322,DB00588,Fluticasone Propionate
,22796247,trough,"However, morning trough values might have been affected by higher placebo response after morning dosing (18.8 vs 8.8 L/min).","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],8.8,105323,DB00588,Fluticasone Propionate
,22796247,Trough PEF,"Trough PEF improved relative to placebo (P ≤ 0.005), with little difference between FF Rotadisk 100 μg morning (19 L/min) and evening (16 L/min) dosing, as with other efficacy measures.","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],19,105324,DB00588,Fluticasone Propionate
,22796247,Trough PEF,"Trough PEF improved relative to placebo (P ≤ 0.005), with little difference between FF Rotadisk 100 μg morning (19 L/min) and evening (16 L/min) dosing, as with other efficacy measures.","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],16,105325,DB00588,Fluticasone Propionate
,24152086,Absolute bioavailability,Absolute bioavailability was greater (36%-55%) in all East Asian groups than for Caucasian subjects following inhaled FF 800 μg.,Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152086/),%,36,105370,DB00588,Fluticasone Propionate
,24152086,Absolute bioavailability,Absolute bioavailability was greater (36%-55%) in all East Asian groups than for Caucasian subjects following inhaled FF 800 μg.,Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152086/),%,55,105371,DB00588,Fluticasone Propionate
,24152086,time for 90% to be absorbed [t90],Deconvolution analysis suggested inhaled FF resided in the lung of East Asian subjects longer than for Caucasians (time for 90% to be absorbed [t90]: 29.1-30.8 h vs. 21.4 h).,Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152086/),h,29.1-30.8,105372,DB00588,Fluticasone Propionate
,24152086,time for 90% to be absorbed [t90],Deconvolution analysis suggested inhaled FF resided in the lung of East Asian subjects longer than for Caucasians (time for 90% to be absorbed [t90]: 29.1-30.8 h vs. 21.4 h).,Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152086/),h,21.4,105373,DB00588,Fluticasone Propionate
,24142782,ΔmPEF,The primary endpoint was a mean change in morning PEF during a 12-week course of therapy (ΔmPEF of 15 L/min was considered as statistically significant).,"Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24142782/),[l] / [min],15,112794,DB00588,Fluticasone Propionate
,11140428,time for absorption of 50%,"The mean time for absorption of 50% of the bioavailable dose was 1.6, 2.4, and 2.2 hours for the Diskhaler, Diskus and MDI, respectively.","Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140428/),h,1.6,117773,DB00588,Fluticasone Propionate
,11140428,time for absorption of 50%,"The mean time for absorption of 50% of the bioavailable dose was 1.6, 2.4, and 2.2 hours for the Diskhaler, Diskus and MDI, respectively.","Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140428/),h,2.4,117774,DB00588,Fluticasone Propionate
,11140428,time for absorption of 50%,"The mean time for absorption of 50% of the bioavailable dose was 1.6, 2.4, and 2.2 hours for the Diskhaler, Diskus and MDI, respectively.","Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140428/),h,2.2,117775,DB00588,Fluticasone Propionate
exceeds,16159619,time to steady state,Accumulation of fluticasone concentrations suggests that time to steady state exceeds 1 week of treatment with MDI.,Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16159619/),week,1,120351,DB00588,Fluticasone Propionate
,11167672,systemic exposure,"The mean systemic exposure, for both formulations was 8.5 pg x ml(-1) x h (drops) and 67.5 pg x ml(-1) x h (spray).",Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11167672/),[h·pg] / [ml],8.5,124049,DB00588,Fluticasone Propionate
,11167672,systemic exposure,"The mean systemic exposure, for both formulations was 8.5 pg x ml(-1) x h (drops) and 67.5 pg x ml(-1) x h (spray).",Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11167672/),[h·pg] / [ml],67.5,124050,DB00588,Fluticasone Propionate
,11167672,absolute bioavailabilities,"Mean absolute bioavailabilities were estimated to be 0.06% (drops) and 0.51% (spray), by reference to historical intravenous data.",Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11167672/),%,0.06,124051,DB00588,Fluticasone Propionate
,11167672,absolute bioavailabilities,"Mean absolute bioavailabilities were estimated to be 0.06% (drops) and 0.51% (spray), by reference to historical intravenous data.",Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11167672/),%,0.51,124052,DB00588,Fluticasone Propionate
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,3.07,136756,DB00588,Fluticasone Propionate
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,6.21,136757,DB00588,Fluticasone Propionate
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,0.84,136758,DB00588,Fluticasone Propionate
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,1.50,136759,DB00588,Fluticasone Propionate
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136760,DB00588,Fluticasone Propionate
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136761,DB00588,Fluticasone Propionate
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136762,DB00588,Fluticasone Propionate
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136763,DB00588,Fluticasone Propionate
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,15.5,136764,DB00588,Fluticasone Propionate
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,50.8,136765,DB00588,Fluticasone Propionate
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,4.41,136766,DB00588,Fluticasone Propionate
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,12.78,136767,DB00588,Fluticasone Propionate
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,1.08,136768,DB00588,Fluticasone Propionate
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,0.09,136769,DB00588,Fluticasone Propionate
,17523699,clearance rate,"The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),[l] / [h],228,142575,DB00588,Fluticasone Propionate
,17523699,protein binding fraction,Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%).,Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),%,98-99,142576,DB00588,Fluticasone Propionate
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,332,142577,DB00588,Fluticasone Propionate
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,183,142578,DB00588,Fluticasone Propionate
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,1800,142579,DB00588,Fluticasone Propionate
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,2200,142580,DB00588,Fluticasone Propionate
,11762560,terminal half-life,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,3.5,145765,DB00588,Fluticasone Propionate
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,3.9,145766,DB00588,Fluticasone Propionate
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,10.1,145767,DB00588,Fluticasone Propionate
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,12.0,145768,DB00588,Fluticasone Propionate
,11762560,mean absorption times (MAT),"Using previously reported intravenous data, the mean absorption times (MAT) were calculated to be around 2 hours and 7 hours for BUD and FP respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,2,145769,DB00588,Fluticasone Propionate
,11762560,mean absorption times (MAT),"Using previously reported intravenous data, the mean absorption times (MAT) were calculated to be around 2 hours and 7 hours for BUD and FP respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,7,145770,DB00588,Fluticasone Propionate
<,11140434,absolute oral bioavailability,At a dose of 10 mg twice daily the absolute oral bioavailability of the drug was <1% when a liquid chromatography-mass spectrometry assay was used to assess plasma concentrations.,Bioavailability of orally administered micronised fluticasone propionate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140434/),%,1,155342,DB00588,Fluticasone Propionate
,10727131,analysis time,"The method is robust, rapid (analysis time of 2 min), selective and hence is ideally suited for pharmacokinetic investigations involving inhalation of therapeutic doses of FP.",A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10727131/),min,2,156224,DB00588,Fluticasone Propionate
,14740785,absolute bioavailability,"Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51.9% (28.2) and 46.9% (30.3) in patients with allergic rhinitis with and without treatment with fluticasone propionate, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,51.9,163996,DB00588,Fluticasone Propionate
,14740785,absolute bioavailability,"Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51.9% (28.2) and 46.9% (30.3) in patients with allergic rhinitis with and without treatment with fluticasone propionate, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,46.9,163997,DB00588,Fluticasone Propionate
,14740785,maximum concentration (Cmax),"Mean maximum concentration (Cmax) values were 3.02 and 3.56 ng/ml, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),[ng] / [ml],3.02,163998,DB00588,Fluticasone Propionate
,14740785,maximum concentration (Cmax),"Mean maximum concentration (Cmax) values were 3.02 and 3.56 ng/ml, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),[ng] / [ml],3.56,163999,DB00588,Fluticasone Propionate
,14740785,Bioavailability,Bioavailability values for both intranasal treatments were lower than those in healthy volunteers (57%).,Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,57,164000,DB00588,Fluticasone Propionate
,14740785,time to Cmax (Tmax),"Median time to Cmax (Tmax) values were significantly different (p=0.02) for treatments B and C (15 and 30 min, respectively) using rank-transformed Tmax for ANOVA.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),min,15,164001,DB00588,Fluticasone Propionate
,14740785,time to Cmax (Tmax),"Median time to Cmax (Tmax) values were significantly different (p=0.02) for treatments B and C (15 and 30 min, respectively) using rank-transformed Tmax for ANOVA.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),min,30,164002,DB00588,Fluticasone Propionate
,31943257,peak concentration (Cmax ),The fluticasone propionate peak concentration (Cmax ) ranged from 5.97 to 200 pg/mL.,"Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),[pg] / [ml],5.97 to 200,168283,DB00588,Fluticasone Propionate
,31943257,time to reach Cmax (Tmax ),"Compared with am-fasted dosing, am-fed dosing was associated with a modestly higher Cmax (∼21%) but lower net exposure (area under the concentration-time curve ∼56% difference) and shorter time to reach Cmax (Tmax ) (Tmax fasted = 10 hours, fed = 5 hours).","Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),h,10,168284,DB00588,Fluticasone Propionate
,31943257,Tmax,"Compared with am-fasted dosing, am-fed dosing was associated with a modestly higher Cmax (∼21%) but lower net exposure (area under the concentration-time curve ∼56% difference) and shorter time to reach Cmax (Tmax ) (Tmax fasted = 10 hours, fed = 5 hours).","Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),h,10,168285,DB00588,Fluticasone Propionate
,31943257,Tmax,"Compared with am-fasted dosing, am-fed dosing was associated with a modestly higher Cmax (∼21%) but lower net exposure (area under the concentration-time curve ∼56% difference) and shorter time to reach Cmax (Tmax ) (Tmax fasted = 10 hours, fed = 5 hours).","Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),h,5,168286,DB00588,Fluticasone Propionate
,31943257,Tmax,"Tmax with hs dosing (14 hours) was later than that with am dosing (Tmax fasted = 10 hours, fed = 5 hours).","Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),h,14,168287,DB00588,Fluticasone Propionate
,31943257,Tmax,"Tmax with hs dosing (14 hours) was later than that with am dosing (Tmax fasted = 10 hours, fed = 5 hours).","Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),h,10,168288,DB00588,Fluticasone Propionate
,31943257,Tmax,"Tmax with hs dosing (14 hours) was later than that with am dosing (Tmax fasted = 10 hours, fed = 5 hours).","Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31943257/),h,5,168289,DB00588,Fluticasone Propionate
,32133324,half-lives,"FTS, SM, and TTP rapidly reached maximum plasma concentration after inhalation (0.08-3.00 h, 0.03-0.10 h and 0.03-0.10 h, respectively) and were eliminated with mean half-lives of 9.29-10.44 h, 6.09-12.39 h and 0.25-47.42 h, respectively.","Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133324/),h,9.29-10.44,172237,DB00588,Fluticasone Propionate
,32133324,half-lives,"FTS, SM, and TTP rapidly reached maximum plasma concentration after inhalation (0.08-3.00 h, 0.03-0.10 h and 0.03-0.10 h, respectively) and were eliminated with mean half-lives of 9.29-10.44 h, 6.09-12.39 h and 0.25-47.42 h, respectively.","Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133324/),h,6.09-12.39,172238,DB00588,Fluticasone Propionate
,32133324,half-lives,"FTS, SM, and TTP rapidly reached maximum plasma concentration after inhalation (0.08-3.00 h, 0.03-0.10 h and 0.03-0.10 h, respectively) and were eliminated with mean half-lives of 9.29-10.44 h, 6.09-12.39 h and 0.25-47.42 h, respectively.","Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133324/),h,0.25-47.42,172239,DB00588,Fluticasone Propionate
,19302910,FP,"The only notable differences were mean FP for particle sizes 2.3 to 3.2 microm (21.4 microg/dose for RPID, 25.6 microg/dose for Diskus) and for sizes 4.0 to 6.2 microm (17.3 microg/dose for RPID, 11.7 microg/dose for Diskus).","Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302910/),,17,181554,DB00588,Fluticasone Propionate
,19302910,maximum heart rate,"A small but statistically significant increase in maximum heart rate (5 beats/min) was noted in the RPID group (ratio, 1.05 [95% CI, 1.01 to 1.10]; P = 0.029).","Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302910/),[beats] / [min],5,181555,DB00588,Fluticasone Propionate
,22356350,systemic bioavailabilities,"The systemic bioavailabilities of marketed AZE and FP nasal spray products have been established at about 40% and 1% only, respectively. •","Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22356350/),%,40,185132,DB00588,Fluticasone Propionate
,22356350,systemic bioavailabilities,"The systemic bioavailabilities of marketed AZE and FP nasal spray products have been established at about 40% and 1% only, respectively. •","Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22356350/),%,1,185133,DB00588,Fluticasone Propionate
≤,22356350,C(max),Study 1: Average FP C(max) was very low with all products (≤ 10 pg ml(-1) ).,"Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22356350/),[pg] / [ml],10,185134,DB00588,Fluticasone Propionate
,22356350,C(max),"Corresponding outcomes for C(max) were 102.7 (92.1, 114.4) and 107.3 (92.6, 124.3).","Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22356350/),,102.7,185135,DB00588,Fluticasone Propionate
,22356350,C(max),"Corresponding outcomes for C(max) were 102.7 (92.1, 114.4) and 107.3 (92.6, 124.3).","Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22356350/),,107.3,185136,DB00588,Fluticasone Propionate
,30640475,concentration-time,"FP concentration-time profiles in the flow-past perfusate were similar irrespective of the medium used in the Dissolv It chamber (∼0.04-0.07%/min), but these were significantly lower than transfer of drug from air-to-perfusate in isolated perfused lungs (0.12%/min).","Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30640475/),[%] / [min],∼0,185378,DB00588,Fluticasone Propionate
,30640475,transfer of,"FP concentration-time profiles in the flow-past perfusate were similar irrespective of the medium used in the Dissolv It chamber (∼0.04-0.07%/min), but these were significantly lower than transfer of drug from air-to-perfusate in isolated perfused lungs (0.12%/min).","Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30640475/),[%] / [min],0.12,185379,DB00588,Fluticasone Propionate
,10950233,plasma area under curve,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [h·ml],1082,186017,DB00588,Fluticasone Propionate
,10950233,plasma area under curve,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [h·ml],2815,186018,DB00588,Fluticasone Propionate
,10950233,maximum concentrations,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [ml],117,186019,DB00588,Fluticasone Propionate
,10950233,maximum concentrations,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [ml],383,186020,DB00588,Fluticasone Propionate
,10950233,systemic bioavailability,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),,10.1,186021,DB00588,Fluticasone Propionate
,10950233,systemic bioavailability,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),%,21.4,186022,DB00588,Fluticasone Propionate
,31364911,AUC(0-t),"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,1,186310,DB00588,Fluticasone Propionate
,31364911,AUC(0-t),"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,0,186311,DB00588,Fluticasone Propionate
,31364911,Cmax ratios,"Estimated AUC(0-t) and Cmax ratios for salmeterol were, respectively, 1.08 (1.04-1.11) and 1.00 (0.94-1.04) for 100/50 μg FP/S, 1.03 (0.99-1.07) and 0.93 (0.87-1.00) for 250/50 μg, and 1.00 (0.96-1.04) and 0.86 (0.81-0.91) for 500/50 μg.",Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364911/),,1,186312,DB00588,Fluticasone Propionate
,20150524,first-order rate constant,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],4.07,187808,DB00588,Fluticasone Propionate
,20150524,relative clearance,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],890,187809,DB00588,Fluticasone Propionate
,20150524,volume of distribution,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,9800,187810,DB00588,Fluticasone Propionate
,20150524,first-order absorption rate constant,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],2.63,187811,DB00588,Fluticasone Propionate
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],202,187812,DB00588,Fluticasone Propionate
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],271,187813,DB00588,Fluticasone Propionate
,20150524,volume of distribution,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,947,187814,DB00588,Fluticasone Propionate
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],3440,187815,DB00588,Fluticasone Propionate
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],4310,187816,DB00588,Fluticasone Propionate
,27026339,CL/F,CL/F was 257 L/h and V c/F was 804 L.,Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27026339/),[l] / [h],257,194346,DB00588,Fluticasone Propionate
,27026339,V c/F,CL/F was 257 L/h and V c/F was 804 L.,Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27026339/),l,804,194347,DB00588,Fluticasone Propionate
,27026339,AUC0-24,AUC and C max increased with increasing UMEC dose (once-daily 15.6-250 mcg: AUC0-24 median: 64.7-863 pg h/mL; C max median: 10.6-256 pg/mL).,Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27026339/),[h·pg] / [ml],64.7-863,194348,DB00588,Fluticasone Propionate
,27026339,C max,AUC and C max increased with increasing UMEC dose (once-daily 15.6-250 mcg: AUC0-24 median: 64.7-863 pg h/mL; C max median: 10.6-256 pg/mL).,Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27026339/),[pg] / [ml],10.6-256,194349,DB00588,Fluticasone Propionate
,25700806,excretion,Urinary UMEC excretion following FF/UMEC was low (~1.5% over 24 h) and unlikely to have impacted upon PK comparisons.,"A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700806/),%,1.5,196760,DB00588,Fluticasone Propionate
,12680886,plasma AUC,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [h·ml],1961,201549,DB00588,Fluticasone Propionate
,12680886,plasma AUC,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [h·ml],2996,201550,DB00588,Fluticasone Propionate
,12680886,Cmax,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [ml],235,201551,DB00588,Fluticasone Propionate
,12680886,Cmax,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [ml],421,201552,DB00588,Fluticasone Propionate
,11825095,peak concentration,"In patients who inhaled salmeterol 50microg twice daily for 10 months, a second peak concentration of 0.07 to 0.2 microg/L occurred 45 to 90 minutes after inhalation, probably because of the gastrointestinal absorption of the swallowed drug.",Clinical pharmacokinetics of salmeterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),[μg] / [l],0.07 to 0.2,203516,DB00588,Fluticasone Propionate
,11825095,elimination half-life,"The xinafoate moiety has no apparent pharmacological activity, is highly protein bound (>99%), largely to albumin, and has a long elimination half-life of about 12 to 15 days in healthy individuals.",Clinical pharmacokinetics of salmeterol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),d,12 to 15,203517,DB00588,Fluticasone Propionate
,11825095,steady-state concentrations,"For this reason, it accumulates in plasma during repeated administration, with steady-state concentrations reaching about 80 to 90 microg/L in patients treated with salmeterol 50microg twice daily for several months.",Clinical pharmacokinetics of salmeterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825095/),[μg] / [l],80 to 90,203518,DB00588,Fluticasone Propionate
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],334,204818,DB00588,Fluticasone Propionate
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],357,204819,DB00588,Fluticasone Propionate
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],366,204820,DB00588,Fluticasone Propionate
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],297,204821,DB00588,Fluticasone Propionate
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],336,204822,DB00588,Fluticasone Propionate
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],328,204823,DB00588,Fluticasone Propionate
,17825692,AUC(0-tau),The geometric mean AUC(0-tau) for 880 microg IN was 74.9 pg x mL/h and geometric mean AUC(0-infinity) for 250 microg IV was 4259 pg x mL/h.,Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825692/),[ml·pg] / [h],74.9,207728,DB00588,Fluticasone Propionate
,17825692,AUC(0-infinity),The geometric mean AUC(0-tau) for 880 microg IN was 74.9 pg x mL/h and geometric mean AUC(0-infinity) for 250 microg IV was 4259 pg x mL/h.,Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825692/),[ml·pg] / [h],4259,207729,DB00588,Fluticasone Propionate
,17825692,absolute bioavailability,"The geometric mean of the absolute bioavailability of fluticasone furoate nasal spray in these healthy subjects was 0.50% (90% CI, 0.34%-0.74%).",Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825692/),%,0.50,207730,DB00588,Fluticasone Propionate
,17825692,absolute bioavailability,The geometric mean of the absolute bioavailability of fluticasone furoate 880 microg IN qSh for 10 doses in these healthy subjects was low--0.50%.,Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825692/),%,0.50,207731,DB00588,Fluticasone Propionate
,20884303,overall recovery,"An efficient solid-phase extraction (SPE) procedure for plasma samples yielded extremely clean extracts with overall recovery of 104.3% and 95.7% for triamcinolone acetonide (TA) and fluticasone propionate, respectively.",Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20884303/),%,104.3,221211,DB00588,Fluticasone Propionate
,20884303,overall recovery,"An efficient solid-phase extraction (SPE) procedure for plasma samples yielded extremely clean extracts with overall recovery of 104.3% and 95.7% for triamcinolone acetonide (TA) and fluticasone propionate, respectively.",Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20884303/),%,95.7,221212,DB00588,Fluticasone Propionate
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,39,221734,DB00588,Fluticasone Propionate
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,13,221735,DB00588,Fluticasone Propionate
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,21,221736,DB00588,Fluticasone Propionate
,23719680,AUC,"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,556",223676,DB00588,Fluticasone Propionate
,23719680,AUC,"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,686",223677,DB00588,Fluticasone Propionate
,23719680,maximum effect (AUC50),"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,556",223678,DB00588,Fluticasone Propionate
,23719680,maximum effect (AUC50),"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,686",223679,DB00588,Fluticasone Propionate
,23719680,AUC50,"The values of AUC50 of 1,556 and 1,686 pg·h/mL, respectively, are several times higher than average fluticasone furoate AUC24 values observed at clinical doses of fluticasone furoate (≤200 μg).",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,556",223680,DB00588,Fluticasone Propionate
,23719680,AUC50,"The values of AUC50 of 1,556 and 1,686 pg·h/mL, respectively, are several times higher than average fluticasone furoate AUC24 values observed at clinical doses of fluticasone furoate (≤200 μg).",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,686",223681,DB00588,Fluticasone Propionate
,23719680,AUC24,"The models predict a fluticasone furoate AUC24 of 1,000 pg·h/mL would be required to reduce 24-h serum cortisol or 24-h urine cortisol excretion by 20 and 17 %, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,000",223682,DB00588,Fluticasone Propionate
,31659803,terminal half-life,GB001 was well tolerated and rapidly absorbed with a 14.5-hour terminal half-life.,"A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31659803/),h,14.5,231466,DB00588,Fluticasone Propionate
,31659803,forced expiratory volume in 1 second,"Greater effects on forced expiratory volume in 1 second were observed in the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207 mL [95% CI: -283, 698];133 mL [95% CI: -422, 687], respectively).","A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31659803/),ml,207,231467,DB00588,Fluticasone Propionate
,31659803,forced expiratory volume in 1 second,"Greater effects on forced expiratory volume in 1 second were observed in the high baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207 mL [95% CI: -283, 698];133 mL [95% CI: -422, 687], respectively).","A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31659803/),ml,133,231468,DB00588,Fluticasone Propionate
,15792395,half-life,Reports characterizing the pharmacokinetics of inhaled fluticasone propionate (FP) using compartmental approaches have suggested that the absorption of FP into the systemic circulation is rapid with a half-life of approximately 10 min.,Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792395/),min,10,240180,DB00588,Fluticasone Propionate
,15792395,absorption,"The absorption, distribution and elimination half-lives resulted to be 3.8 h, 9.9 min and 13.6 h, respectively, consistent with the high lipophilicity and sustained dissolution characteristics observed in vitro.",Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792395/),h,3.8,240181,DB00588,Fluticasone Propionate
,15792395,absorption,"The absorption, distribution and elimination half-lives resulted to be 3.8 h, 9.9 min and 13.6 h, respectively, consistent with the high lipophilicity and sustained dissolution characteristics observed in vitro.",Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792395/),min,9.9,240182,DB00588,Fluticasone Propionate
,15792395,distribution,"The absorption, distribution and elimination half-lives resulted to be 3.8 h, 9.9 min and 13.6 h, respectively, consistent with the high lipophilicity and sustained dissolution characteristics observed in vitro.",Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792395/),min,9.9,240183,DB00588,Fluticasone Propionate
,15792395,elimination half-lives,"The absorption, distribution and elimination half-lives resulted to be 3.8 h, 9.9 min and 13.6 h, respectively, consistent with the high lipophilicity and sustained dissolution characteristics observed in vitro.",Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792395/),h,13.6,240184,DB00588,Fluticasone Propionate
,28786292,half-life,Highest concentrations in plasma following 12 mg administration occurred 1 day postdose and declined with a half-life of approximately 45 days.,Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28786292/),d,45,240317,DB00588,Fluticasone Propionate
,28786292,half-life,Highest concentrations of fluticasone propionate in synovial fluid and cartilage generally occurred 5 days postdose in both dose groups and declined with a half-life of approximately 11 to 14 days.,Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28786292/),d,11 to 14,240318,DB00588,Fluticasone Propionate
,9131947,Systemic availability,"Systemic availability, mainly attributable to pulmonary deposition, was 15.6 [13.6-18.0]% of the nominal dose.",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131947/),%,15.6,247414,DB00588,Fluticasone Propionate
,23094685,aerodynamic,Aerosols of FF with mass median aerodynamic diameters ranging from 2.2 to 3.2 μm were generated with the DustGun aerosol generator.,"Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094685/),μm,2.2 to 3.2,249844,DB00588,Fluticasone Propionate
,23094685,half-life of pulmonary retention,"Following inhalation, FF was slowly disappearing from both the IPL and the lungs of the EIR, with a half-life of pulmonary retention of 4.3-4.9 hr for all three exposure series.","Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094685/),h,4.3-4.9,249845,DB00588,Fluticasone Propionate
,23094685,Cmax,"For the low exposure levels, the concentration curve of FF in the IPL perfusate was similar in shape to that in venous blood of the EIR, with a Cmax of 1.0 and 0.8 nM for the IPL and the EIR, respectively.","Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094685/),nM,1.0,249846,DB00588,Fluticasone Propionate
,23094685,Cmax,"For the low exposure levels, the concentration curve of FF in the IPL perfusate was similar in shape to that in venous blood of the EIR, with a Cmax of 1.0 and 0.8 nM for the IPL and the EIR, respectively.","Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094685/),nM,0.8,249847,DB00588,Fluticasone Propionate
,31669821,absorption/emission wavelength (λabs/em),"Spectrofluorimetric detection was performed using absorption/emission wavelength (λabs/em) of 286/352 nm and 362/407 nm for FF and VT, respectively.",HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669821/),nm,286/,258003,DB00588,Fluticasone Propionate
,31669821,absorption/emission wavelength (λabs/em),"Spectrofluorimetric detection was performed using absorption/emission wavelength (λabs/em) of 286/352 nm and 362/407 nm for FF and VT, respectively.",HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669821/),nm,352,258004,DB00588,Fluticasone Propionate
,31669821,absorption/emission wavelength (λabs/em),"Spectrofluorimetric detection was performed using absorption/emission wavelength (λabs/em) of 286/352 nm and 362/407 nm for FF and VT, respectively.",HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669821/),nm,362,258005,DB00588,Fluticasone Propionate
,31669821,absorption/emission wavelength (λabs/em),"Spectrofluorimetric detection was performed using absorption/emission wavelength (λabs/em) of 286/352 nm and 362/407 nm for FF and VT, respectively.",HPLC-UV and spectrofluorimetric methods for simultaneous estimation of fluticasone furoate and vilanterol in rabbit plasma: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31669821/),nm,407,258006,DB00588,Fluticasone Propionate
,12173797,Cmax,"Mean +/- SD Cmax from InspirEase (245 +/- 77 pg/ml) was 18% higher than that after E-Z Spacer (199 +/- 58 pg/ml, p < 0.05).",Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173797/),[pg] / [ml],245,266256,DB00588,Fluticasone Propionate
,12173797,Cmax,"Mean +/- SD Cmax from InspirEase (245 +/- 77 pg/ml) was 18% higher than that after E-Z Spacer (199 +/- 58 pg/ml, p < 0.05).",Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173797/),[pg] / [ml],199,266257,DB00588,Fluticasone Propionate
,12173797,AUC0-6,"Mean +/- SD AUC0-6 from InspirEase (1103 +/- 305 pg x hr(-1) x ml(-1) was 22% higher than that delivered from E-Z Spacer (863 +/- 258 pg x hr(-1) x ml(-1), p = 0.06).",Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173797/),[pg] / [hr·ml],1103,266258,DB00588,Fluticasone Propionate
,12173797,AUC0-6,"Mean +/- SD AUC0-6 from InspirEase (1103 +/- 305 pg x hr(-1) x ml(-1) was 22% higher than that delivered from E-Z Spacer (863 +/- 258 pg x hr(-1) x ml(-1), p = 0.06).",Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12173797/),[pg] / [hr·ml],863,266259,DB00588,Fluticasone Propionate
,11294367,pulse rate,"With the exception of a higher pulse rate after repeat administration of salmeterol [66.2 beats per minute (bpm) versus 63.6 bpm], there were no significant differences between the single-dose and repeat-dose salmeterol groups.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),[beats·min] / [bpm],66.2,273152,DB00588,Fluticasone Propionate
,11294367,pulse rate,"With the exception of a higher pulse rate after repeat administration of salmeterol [66.2 beats per minute (bpm) versus 63.6 bpm], there were no significant differences between the single-dose and repeat-dose salmeterol groups.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),bpm,63.6,273153,DB00588,Fluticasone Propionate
,11294367,excretion,"Fluticasone propionate reduced 24-h urinary cortisol excretion (22.4 microg compared with 48.6 microg with placebo), but this was unaffected by the co-administration of salmeterol.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),μg,22.4,273154,DB00588,Fluticasone Propionate
,11294367,excretion,"Fluticasone propionate reduced 24-h urinary cortisol excretion (22.4 microg compared with 48.6 microg with placebo), but this was unaffected by the co-administration of salmeterol.",Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294367/),μg,48.6,273155,DB00588,Fluticasone Propionate
